Broadridge Financial Solutions reports its fiscal Q3 2026 results today with options traders positioned more defensively than they have been in months — even as short sellers quietly retreat.
The clearest signal heading into the print is in options. The put/call ratio has climbed to 1.59, running 1.67 standard deviations above its 20-day average of 1.30. That is not a panic reading — the 52-week high is 3.57 — but it marks a distinct shift from the relatively neutral positioning seen through most of March. The move to more defensive hedging has coincided with a rough April: the stock has fallen 5.8% over the past month to $153.98, including a 4.2% drop in the most recent session alone.
Short interest tells a different story. Bears have been covering, not building. SI has dropped 28% over the past month to just 2.7% of the free float — a level that by most measures is not elevated. Cost to borrow is a minimal 0.39%, and borrow availability remains extremely loose, meaning the lending market presents no friction for either side. The short score has also drifted lower over the past two weeks, from around 34.5 to 32.0. Short sellers are not the ones expressing concern here.
The debate centres on Broadridge's revenue mix and near-term margin trajectory. The bull case rests on recurring revenue, which grew 9.2% year-over-year to $1.07 billion last quarter, plus a 24% jump in closed sales that suggests demand remains firm. DA Davidson and Needham both reiterate Buy ratings, with targets of $228 and $255 respectively — well above the current price. The bear case is harder to dismiss: event-driven revenue fell 27.3% last quarter, adjusted operating margins are guided flat at 20–21%, and a weaker macro backdrop could cool the investment activity that drives Broadridge's transactional revenue. JPMorgan holds a Neutral rating after cutting its target from $273 to $229 following the February print. The mean analyst target of $233.75 implies roughly 52% upside from here — a large gap that reflects the magnitude of the stock's sell-off more than any fresh bullishness.
One data point worth noting: CEO Tim Gokey bought 5,300 shares at ~$194.49 in early March, committing just over $1 million of personal capital. That purchase came well above today's price and follows a pattern of executive selling from the President and a Vice President in late 2025. The net 90-day insider position is a modest net buy, but the CEO's willingness to step in at higher prices adds a layer of signal that the market has priced in more deterioration than management believes is warranted.
The earnings release will test whether the recurring revenue engine can continue to offset the event-driven drag — and whether management's 9–12% EPS growth guidance survives contact with a market that has spent the past month voting no.
See the live data behind this article on ORTEX.
Open BR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
